Background The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011. Objective The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review. Methods We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables. Results We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time. Conclusion RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.
The influx of new oncologic technologies to treat renal cell carcinoma (RCC) sparked interest in assessing the economics of RCC as evident by over 50 RCC-related economic studies published between June 2010 and August 2018
For localized RCC, minimally invasive procedures had comparable costs as open surgery for radical nephrectomies but had some cost advantage in partial nephrectomies For metastatic RCC, cost studies found pazopanib to have lower costs than sunitinib in the first-line setting whereas cost-effectiveness studies tended to favor everolimus over cabozantinib and nivolumab
Introduction
Kidney cancer is among the top 10 cancers for both men and women in the United States (US), accounting for approximately 4% of new cancer cases estimated in 2018 [1, 2] . Globally, the estimated incidence of kidney cancer from GLOBOCAN was 337,860 in 2012 [3] . In the US alone, it was estimated that 65,340 new cases of kidney cancer would be diagnosed and 14,970 Americans would die from kidney cancer in 2018 [1, 2] . The average age of kidney cancer patients in the US is 64 years [4] , and, overall, men are twice as likely to be diagnosed with kidney cancer as women [1] . Risk factors known to be strongly associated with kidney cancer include obesity and tobacco use, while other risk factors include high blood pressure, chronic renal failure, and environmental exposure to chemicals such as trichloroethylene [1] . Of the various subtypes of kidney cancer, renal cell carcinoma (RCC) is the predominant form, accounting for 80-85% of all kidney cancers [4] . The majority (approximately 65%) of kidney cancers are diagnosed at the localized stage, with regional or distant stage each accounting for approximately 16% of the diagnosed cases [2] . The 5-year survival rate for patients with stage I RCC is more than 90%, however the recurrence rate is close to 40% for patients with stage II/III RCC [4] .
For localized RCC, radical nephrectomy (RN) performed as open surgery has been the standard of care in the past [5] . As medical technology advances, microinvasive techniques such as laparoscopic procedures, with or without robotic assistance, are becoming increasingly common in the surgical treatment of RCC [5] . At the same time, more small or indolent renal cell tumors have been detected as incidental findings while patients underwent imaging for other diseases. For these tumors, concerns have been voiced regarding whether treatment with RN, or even partial nephrectomy (PN), may be too invasive and that active surveillance or ablation should be considered as viable alternatives [5] . The role of adjuvant treatment for RCC remains unclear and is currently under active clinical investigation [6] .
For advanced or metastatic RCC (mRCC), systemic treatment is the standard of care, with a subset of patients also benefiting from nephrectomy [6] . Prognostic models have been used to guide treatment selection for patients with RCC [4, 6] . Patients with mRCC have benefited considerably from scientific advances in cancer drug discoveries. As of 19 May 2016, 12 anticancer medications have been approved by the FDA for the treatment of RCC in the US [7] . These drugs include immunotherapy (e.g. high-dose interleukin [IL]-2 or checkpoint inhibitors such as nivolumab and ipilimumab) and targeted therapy. Compared with other cancers, a relatively large number of targeted therapy agents, both in oral and infused formulations, are indicated for RCC, including tyrosine kinase inhibitors (TKIs; e.g. sunitinib, sorafenib, pazopanib, axitinib, cabozantinib, and lenvatinib), antivascular endothelial growth factor (anti-VEGF) agents (e.g. bevacizumab), and mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus and everolimus).
A two-part article on the economic burden of RCC was published in PharmacoEconomics in 2011, including a comprehensive review (Part I) [8] and an analysis of databases in the US [9] . This 2011 review article covered studies published between 1 January 2000 and 15 June 2010, and reported substantial economic burden of RCC, with estimated annual costs ranging from $0.6 billion to $5.2 billion (2009 US$) in the US [8] . Given the technological advances in oncology in the past 10 years, the high price tag typically associated with new medical technologies, and the influx of new oncologic technologies to the treatment of RCC, the economic burden of RCC is likely to be considerably higher today. The objective of this study was to conduct a comprehensive review of economic studies related to the treatment of RCC for studies published after June 2010, as an update to the review article published in 2011 [8] . The economic studies covered in this review include cost, cost-effectiveness, and cost-of-illness studies. This updated review will help patients, clinicians, and payers better understand how the changing landscape of cancer treatment affects the economic burden of RCC.
Methods
In our updated review, we conducted a literature search in the PubMed, EMBASE, and Cochrane Library electronic databases. Our search covered articles written in the English language published between June 2010 and August 2018. For the PubMed searches, we combined the search filters recommended in the literature for costs or economic studies [10] . Specifically, we applied the following search terms for costs/economic studies: "((("costs and cost analysis" [MeSH] [MeSH] OR health care costs[MeSH:noexp])))." We then crossreferenced the above search filter with search terms related to RCC, "((renal) OR (kidney)) AND ((carcinoma) OR (neoplasm) OR (cancer))", to identify relevant articles. For articles in the Cochrane Library and EMBASE, we modified the search strategy as follows: [((cost.ab or cost.ti or cost.kw) AND ((carcinoma or neoplasm or cancer).ab or (carcinoma or neoplasm or cancer).ti or (carcinoma or neoplasm or cancer).kw) AND ((renal or kidney).ab (renal or kidney).ti or (renal or kidney).kw))] for EMBASE, and [((renal) OR (kidney)) AND ((carcinoma) OR (neoplasm) OR (cancer)) AND cost] for the Cochrane Library. We then removed duplicates identified from different sources, and two independent reviewers (Chien and Shih) reviewed the titles and/or abstracts to select potentially relevant studies. We excluded institution-specific studies because we were interested in the economic burden from the population perspective. In addition, to enhance the clinical relevance of this review regarding the cost effectiveness of new therapies for RCC, we limited our reviews of cost-effectiveness studies to those that included treatments recommended in current practice guidelines [6] . Disagreement regarding the inclusion of articles in this review was resolved by discussion between the two aforementioned reviewers. Articles to be included in our study were finalized after full-text reviews of the papers identified above. Again, these decisions were made by two independent reviewers (Chien and Shih), with disagreement being resolved through discussion. We applied the 24-item checklist in the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement to qualitatively assess articles included in our review [11] .
We categorized the articles identified from the searches above by type of analysis in economic evaluation: costeffectiveness analysis (CEA), cost analysis, or cost-of-illness (COI) analysis. We synthesized information retrieved from the literature into the following components in the summary tables: (1) authors, country, and sponsorship (i.e. whether the study was sponsored by the manufacturer of the drugs or devices under investigation); (2) target population (for all studies) and interventions (for CEA or cost studies); (3) study method, including perspective, parameter sources, discounting, cost type, reference year for cost, time frame, and analytical approach; (4) results, including mean costs and mean effectiveness (for CEA studies) for each intervention, and the incremental costs and incremental effectiveness if costs and effectiveness were not reported separately for each intervention; (5) conclusions, including incremental cost-effectiveness ratios (ICERs) and findings from the sensitivity analyses if available; and (6) comments to summarize other elements of the studies that we considered worth noting.
We used the year reported in the paper as the reference year for cost. If such information was not provided, we then determined the reference year based on the most relevant year of data used, or the year in which the paper was published. All costs in this review were expressed in 2017 US$ in the summary tables, whereas both original and updated dollar values (shown in square brackets if different from the original value) were reported in the text. For studies reporting costs in US$, we normalized the cost estimates to 2017 values using the medical care services component of the Consumer Price Index [12] . For studies that reported costs in other currencies, we converted the estimates to US$ using the Purchasing Power Parity index (PPP) [13] . For the threshold value reported in sensitivity analyses based on a currency other than US$, we quoted the original value as well as US$ converted from the PPP in 2017. Figure 1 depicts the flowchart of the literature search process as suggested by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [14] . As shown, we identified 2317 studies in our initial screening of the PubMed, EMBASE, and Cochrane Library electronic databases. After removing duplicates (i.e. studies identified from more than one data source), we reviewed the title/abstract to exclude studies that did not meet our inclusion criteria, leaving the remaining 76 articles for fulltext review; 52 studies were included in the final analyses. In addition, we also hand-searched the studies included in two systematic reviews [15, 16] identified from our literature search. No additional relevant studies were found from the hand-search. The subsections below are organized by study type, i.e. CEA, cost, and COI (Tables 1, 2, 3) . Articles within each table are subdivided by cancer stage and treatment characteristics (e.g. line of systemic therapy). Before discussing articles included in our review, we note that only 2 of these 52 articles took a societal perspective. Table 4 summarizes the qualitative assessment of each article based on the CHEER checklist.
Results

Review of Cost-Effectiveness Analysis (CEA)
Of the 52 studies in our final analysis, 21 were cost-effectiveness studies (Table 1) . Among the 21 CEA studies that we reviewed, all employed modeling approaches and focused on mRCC patients.
CEA: Metastatic Renal Cell Carcinoma (mRCC), First-Line
Seven articles assessed the first-line treatment of mRCC.
Despite a large number of drugs indicated for mRCC, only five drugs were examined in studies comparing the cost effectiveness of treatment options for current first-line therapy, including pazopanib, sunitinib, sorafenib, IL-2, and bevacizumab in combination with interferon (IFN)-α. Pazopanib was compared with sunitinib in four studies [17] [18] [19] [20] , all of which obtained clinical information from the COM-PARZ (Comparing the Efficacy, Safety and Tolerability of Pazopanib versus Sunitinib) trial [21] , a large, phase III, non-inferiority international trial sponsored by GlaxoSmithKline, the manufacturer of pazopanib. Delea and colleagues supplemented clinical information retrieved from the COM-PARZ trial with the PISCES (Patient Preference Study of Pazopanib versus Sunitinib in Advanced or Metastatic Kidney Cancer) trial, which collected information on patient preference, measured by EQ-5D, as the primary endpoint [17] . All four studies employed a partitioned survival model with three health states (alive with no progression, alive with progression, and dead) and concluded that pazopanib dominated sunitinib. Another three studies assessing the cost effectiveness of first-line treatment compared sunitinib with therapeutic alternatives for patients with mRCC prior to sunitinib becoming available in 2006 [22] [23] [24] . All three studies concluded that sunitinib was more effective and less costly (i.e. the dominating strategy) when compared with bevacizumab plus IFNα. Two of these three studies also included sorafenib in their assessment, and both reported sorafenib was dominated by sunitinib [22, 23] . IL-2 was assessed by Wu et al., and the authors reported that sunitinib was cost effective under the Sunitinib Patient Assistance Program [24] .
CEA: mRCC Second-Line
Fourteen cost-effectiveness studies focused on the secondline treatment of mRCC, and assessed the following drugs: sorafenib, everolimus, temsirolimus, sunitinib, nivolumab, cabozantinib, and axitinib. Seven studies also included best supportive care (BSC) as a comparator [25] [26] [27] [28] [29] [30] [31] . Of the four studies that modeled BSC as the 'standard of care', all published prior to 2015, none concluded BSC was dominated by the new therapy that it was compared against [25] [26] [27] [28] . Two studies that compared sorafenib with BSC, both conducted in Cyprus, concluded that the cost effectiveness of sorafenib largely depended on the drug price [25, 26] . It is worth noting that of these two studies, one was primarily a valuebased pricing study but also included a CEA component [26] . Mihajlovic and colleagues concluded that everolimus was unlikely to be cost effective compared with BSC for mRCC patients refractory to sunitinib [27] , whereas PazAres and colleagues compared sunitinib with BSC and concluded that sunitinib was cost effective for mRCC patients who did not respond to first-line therapy with IFNα or IL-2 [28] .
As more new drugs were approved for second-line therapy of mRCC, BSC became less common in secondline settings, and cost-effectiveness analyses were able to model clinical parameters from head-to-head trials, such as the AXIS (AXItinib vs. Sorafenib in advanced renal cell carcinoma) trial for axitinib versus sorafenib [32] , and the CheckMate 025 trial for nivolumab versus everolimus [33] . Eight studies included both nivolumab and everolimus in the comparators [29] [30] [31] [34] [35] [36] [37] [38] , with both these drugs being directly compared in six studies [29, 31, [34] [35] [36] 38] . Only two of the six studies found nivolumab to be cost effective compared with everolimus. Specifically, Giuliani and Bonetti reported an ICER of approximately $2400 per month of life gained for nivolumab compared with everolimus [29] , while McCrea and colleagues estimated the ICER to be close to $52,000 per quality-adjusted life-year (QALY) gained [35] . The other four studies concluded that nivolumab was unlikely to be more cost effective than everolimus when Inferred from the year of data (2011-2013) as the reference year for cost was not specified in the paper benchmarking against the societal willingness to pay (WTP) of $100,000/QALY [31, 34, 36, 38] . It is worth noting that the study by Giuliani and Bonetti may reflect a partial assessment because their analyses only considered drug cost [29] .
Comparisons between cabozantinib and everolimus were identified in three studies, all of which reported an ICER higher than $150,000 per QALY or LY when cabozantinib was compared with everolimus [30, 37, 38] . Collectively, the literature to date is leaning toward less-favorable costeffectiveness conclusions for newly approved agents for the second-line treatment of mRCC, such as cabozantinib and nivolumab, when compared with everolimus. Two cost-effectiveness analyses modeled sorafenib as the standard of care for second-line therapy. When compared with sorafenib, Casciano and colleagues concluded that everolimus was cost effective for mRCC patients refractory to sunitinib [39] , whereas Petrou reported that it would take a WTP threshold higher than €100,000 for axitinib to be cost effective [40] . In addition to the above study by Petrou [40] , the cost effectiveness of axitinib versus other second-line agents was examined in four other studies [29, 30, 37, 38] .
Edwards et al. [30] and Swallow et al. [38] found axitinib to be dominated by everolimus, while Giuliani and Bonetti [29] found axitinib to be dominated by sorafenib. When cabozantinib was compared with axitinib, Meng and colleagues reported an ICER of $142,194 [₤98,967/QALY] per QALY gained, indicating that cabozantinib was not more cost effective compared with axitinib [37] .
Review of Cost Analysis
Our literature search identified 23 cost studies (Table 2) , the majority of which were observational studies using secondary databases available in the US. The most commonly used database in US-based studies is the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, which links cancer patients in the SEER Program, an epidemiological surveillance system of population-based tumor registries containing data from 17 geographic areas in the US, with a Medicare enrollment file to identify cancer patients in the SEER registry who were eligible for Medicare, and to collect all Medicare claims for these patients in the database [41] . Characterizing uncertainty  1  2  2  5  10  21  Characterizing heterogeneity  20  16  5  41  79  22 Study findings, limitations, generalizability, and current knowledge For studies using claims data, insurance payment was used to quantify costs.
Cost: Localized RCC
Eight studies focused on treatment for localized RCC [42] [43] [44] [45] [46] [47] [48] [49] . As discussed earlier, surgery remains the mainstay of treatment for early-stage RCC, therefore all eight studies (one from the UK, six from the US, and one from Taiwan) included some form of surgical procedure.
Four articles compared open RN (ORN) with laparoscopic RN (LRN) or minimally invasive RN (MIRN) [44] [45] [46] 49] . Using data from the Nationwide Inpatient Sample [45] , the SEER-Medicare Database [44, 46] , and the National Health Insurance Research Database of Taiwan [49] , three of the four studies concluded that costs were comparable between ORN and LRN or MIRN [44, 45, 49] . Among LRN, Golombos and colleauges reported that robotic-assisted RN was associated with higher cost when compared with LRN without robotic assistance [43] . An opposite conclusion was reached in a UK study on PN, in which Camp and colleagues reported that the costs of robotic-assisted PN was lower than open PN or LPN without robotic assistance [42] . A similar comparison was made by Bahler et al. based on a US database [48] ; the authors found that RPN had significantly higher costs than OPN, although the cost difference became statistically insignificant toward the end of their study period. It is worth noting that of the eight cost studies that compared various forms of surgical techniques, the study by Camp et al. was the only study sponsored by Intuitive Surgical Inc., the sole manufacture of robotic surgical systems [42] . Kowalczyk et al. and Larcher et al. compared nephrectomy with less-aggressive management of localized RCC with small tumor size, such as ablation or surveillance [46, 47] . Both studies analyzed SEER-Medicare data and reported higher costs of nephrectomy. The study that included surveillance as a viable option for patients with small renal masses concluded that surveillance was associated with the lowest cost, followed by ablation, then nephrectomy [46] .
Cost: Non-Pharmaceutical Treatment of mRCC
Among the 15 cost studies of mRCC, only one focused on the surgical management of mRCC [50] ; all others examined anticancer medications. Takagi and colleagues conducted a population-based study, using a Japanese database, to explore factors associated with perioperative outcomes of cytoreductive nephrectomy for mRCC, and concluded that the total hospitalization cost of laparoscopic nephrectomy was 3.4% higher than that of open nephrectomy [50] .
Cost: mRCC, Pharmaceutical Treatments, First-Line
Of the eight studies that estimated the costs of anticancer medications as first-line therapy, six compared pazopanib with sunitinib. Despite the difference in study approaches and the definition of costs, all six studies concluded that pazopanib had a lower cost [51] [52] [53] [54] [55] [56] , with the magnitude of the annual cost difference ranging from less than $7200 per patient [52] to more than $20,000 (in 2017 US$) [54] . Ravasio and colleagues compared sunitinib versus bevacizumab plus IFNα from the perspective of the Italian National Health Service (NHS) and found sunitinib to be associated with higher cost [57] . The authors noted that the cost advantage of IFNα could be driven by the terms of the risk-sharing agreement between the Italian NHS and the manufacturer of bevacizumab versus that of sunitinib [57] . Instead of comparing specific agents for mRCC, Soerensen and colleagues compared two classes of anticancer medications in first-line settings, from both payer and societal perspectives, i.e. traditional cytokine immunotherapy (e.g. IL-2) versus targeted therapies [58] . This Danish study found that although drug costs were substantially higher for mRCC patients receiving targeted therapies than those receiving immunotherapy, total healthcare costs were not significantly different between these two groups as higher drug costs of targeted therapies were offset by lower inpatient and radiotherapy costs [58] .
Cost: mRCC, Pharmaceutical Treatments, Second-Line
Two cost studies focused on second-line treatment for mRCC [59, 60] , both of which were US studies comparing axitinib with everolimus. Perrin and colleagues applied a modeling approach to project lifetime costs [60] , whereas Pal and colleagues conducted a retrospective review of medical records to estimate costs per month of progressionfree survival [59] ; both concluded that axitinib had higher costs than everolimus [59, 60] . However, one must exercise caution when interpreting these findings because certain input parameters in the study by Perrin et al. appeared to be biased against axitinib (e.g. longer duration of drug supply for axitinib), and the study by Pal et al. only reflected drug acquisition costs.
Cost: mRCC, Pharmaceutical Treatments, All Lines
Four cost studies explored the treatment costs of mRCC associated with different dosing patterns or treatment pathways without focusing on specific lines of therapy. Suo and colleagues explored clinical outcomes and costs associated with various modifications of the dose and/or schedule of sunitinib to make the drug better tolerated by mRCC patients [61] . Compared with the standard schedule of 50 mg daily, 4 weeks on/2 weeks off, the study found that several doseadjusted sunitinib regimens were associated with lower costs and improved overall and progression-free survival [61] . Geynisman and colleagues stratified patients by whether their first-line treatment of mRCC was an oral or intravenous agent, and compared the treatment patterns and costs within the first year since treatment initiation [62] . The authors further subdivided patients in the intravenous group by whether their treatment regimen consisted of one or more targeted intravenous anticancer medications (i.e. bevacizumab or temsirolimus) [62] . 
Review of Cost-of-Illness (COI) Studies
We identified eight studies that estimated the economic burden of RCC (Table 3) . Of those, only one study included all tumor stages [65] , while the remaining seven focused only on patients with mRCC. Two further studies limited their analyses to costs of adverse events (AEs) associated with targeted therapies used to treat mRCC.
COI: All Stages
Hollenbeak and colleagues analyzed SEER-Medicare data, from 1995 to 2002, and used statistical methods that accounted for censored cost data [66, 67] to estimate the cumulative costs for newly diagnosed elderly RCC patients at 1 and 5 years [65] . The authors applied a net costing approach [68, 69] by identifying a non-cancer control cohort using a propensity score matching method, and estimated RCC-related costs as the difference between the mean cost of the RCC cohort and that of the matched non-cancer controls. 
COI: mRCC
The approval of several targeted therapy agents for mRCC has motivated researchers to study the economic impact of these costly agents on this particular disease stage of RCC. Although this topic was explored in five studies [70] [71] [72] [73] [74] , comparing the economic burden estimated from these studies was not meaningful because of differences in the study cohorts and variations in cost structure across countries, as well as what was captured in costs. Ballali and colleagues estimated the population economic burden for mRCC patients in Italy, but restricted their study to the clinical scenario of using sunitinib and sorafenib as first-and secondline treatment, respectively. The estimated population drug costs for the above scenario was over $5 million for the first year of treatment [70] . Maroun and colleagues explored the impact of targeted therapy on the inpatient costs of mRCC in France by comparing the costs of hospital management between patient cohorts in two time periods (2008 vs. 2012 ).
The study concluded that although the mean hospitalization cost per patient continued to increase over time, the proportion of patients receiving expensive intravenous drugs in a hospital setting has decreased as a result of the increasing use of targeted oral anticancer drugs [72] . Another French study estimated per-patient per-month (PPPM) costs for mRCC patients receiving targeted therapies as first-line treatment and reported that costs of targeted oral agents accounted for more than 50% of the estimated total PPPM cost of €5546 [$6944] [71] . From the societal perspective, Purmonen and colleagues estimated the lifetime treatment costs of mRCC patients who received IFNα as first-line treatment, and conducted budget impact modeling to project the impact of adding sunitinib to the first-line treatment protocol on the 5-year costs of mRCC in Finland. The estimated lifetime costs with IFNα were €32,951 [$41,253 ] and the addition of sunitinib was projected to raise the 5-year national budget from €26 million [$33 million] to €41M ($51 million) [73] . Li and colleagues focused on the out-ofpocket (OOP) costs for Medicare beneficiaries enrolled in the Medicare prescription drug plans (also known as Part D) and reported OOP costs to be substantially lower for those with low-income subsidies compared with those without subsidies (≤ $8 vs. ≥ $3208 per month) [74] .
COI: Adverse Events Associated with Targeted Therapies for mRCC
The economic burden of AEs associated with targeted therapies was examined in two studies [75, 76] . Both studies were observational studies that focused on grade 3 or 4 toxicities with ≥ 5% occurrence, as reported in the trials of any of the four targeted therapy agents (sunitinib, sorafenib, bevacizumab, and pazopanib); data were limited to AEs that could be ascertained from claims data. AEs captured in both studies included abdominal pain, back pain, diarrhea, dyspnea, extremity pain, fatigue/asthenia, hand-foot syndrome, hypertension, lymphopenia, nausea/vomiting, neutropenia, proteinuria, and thrombocytopenia. Instead of directly quantifying costs associated with each AE, both studies estimated the economic burden of targeted therapy-related AEs using the difference in total healthcare costs (not including costs of targeted therapies) within 30 days of the occurrence of AEs between patients with AEs and those without, with 'shadow' index dates assigned to the latter group. After adjusting for differences in patient characteristics between the AE and non-AE groups, the estimated costs of 
Assessment Based on the CHEERS Checklist
The qualitative assessment of each article based on the 24-item CHEERS checklist is provided in the supplementary tables and summarized in Table 4 . Overall, the quality of these studies was acceptable per the criteria set forth in the CHEERS checklist. With the exception of the study by Giuliani and Bonetti [29] , the number of checklist items not addressed in the articles was four or less. In terms of compliance with specific checklist items, most items were addressed by the vast majority of articles included in our review, except for two items: characterizing heterogeneity and currency, price date, and conversion. Specifically, 41 of the 52 articles (approximately 79%) did not examine heterogeneity by exploring the extent to which the differences in costs or cost effectiveness could be explained by variations in patients' baseline characteristics or other factors, whereas approximately 21% (11 of 52) of the studies did not provide sufficient information on the referenced date of costs or methods to normalize costs to a particular year, or the exchange rates used in the currency conversion.
Discussion
The literature search performed for this updated review indicates a growing research interest in the cancer economics of RCC, as demonstrated by more than double the number of studies (n = 52) identified from our current search of articles published between June 2010 and August 2018, compared with 20 studies in our previous review that covered the duration between January 2000 and June 2010. Table 5 summarizes the characteristics of the 52 articles included in this updated review. All but five studies [24, 34, 49, 50, 63] were from authors in Europe or North America, especially in the US (n = 25). Almost half of the studies (n = 25) were sponsored by the manufacturer of the drug or surgical device under investigation, and more than 80% (n = 43) of the studies focused on mRCC. Although the societal perspective is recommended for economic evaluation of healthcare and cost-effectiveness analyses [77] , the vast majority of the studies took the perspective of the healthcare sector. Overall, modeling was the dominant analytical approach in CEA, whereas most cost and COI studies were observational studies using secondary databases. Our review of CEA studies found that as first-line treatment for mRCC, pazopanib dominated sunitinib, which further dominated bevacizumab plus IFNα as well as sorafenib. Findings from CEAs of second-line treatment were less conclusive as the cost effectiveness of a specific agent varied by drug cost or WTP threshold. All CEAs identified from our literature search focused on comparing pharmacological treatments. Perhaps because there was no evidence demonstrating the efficacy of any particular anticancer medication in the adjuvant setting for RCC, except for the recent approval of adjuvant sunitinib by the FDA in the US [78] , all CEAs focused on patients with advanced or metastatic RCC. Several observations in our review of CEA studies warrant further discussion. First, the treatment of RCC, especially mRCC, has dramatically changed in the past decades to the extent that CEA quickly became outdated. For example, our previous review had concluded that sunitinib was likely to be cost effective in both the first-and second-line settings [7] ; however, the current review found several studies that concluded, compared with sunitinib, pazotinib, a new drug that was not available in our previous review in 2011, was more cost effective in the first-line setting. In addition, many recently published studies that assessed the cost effectiveness of second-line therapies no longer included sunitinib as a comparator. For diseases with a large influx of new treatments, it is important to reassess and update the cost-effectiveness literature to stay clinically relevant. Second, although there are close to 20 guidelinecompatible treatment alternatives for mRCC, only 10 agents have been examined in CEAs. This suggests a large knowledge gap on the cost effectiveness of the wide array of treatment options for patients with mRCC. Third, some treatments that may not appear to be cost effective in all settings, such as nivolumab, present a tremendous clinical benefit for a minority of patients (the 'tail of the curve') and cannot be properly captured in traditional CEAs. Lastly, even among the small subset of agents that were better covered in the CEA literature, a high level of repetition was observed. For example, four studies in our review employed nearly identical modeling approaches and had a large proportion of overlapping authors across studies. Of the four studies, the first was published in 2015 using a US-based model [17] . It is reasonable to consider the three studies published subsequent to the first study as country adaptation studies that extended the original model to Canada [18] , UK [19] , and Italy [20] . These rather homogeneous CEA studies raised concern on the representativeness and generalizability of their findings, especially when all studies had the same commercial sponsor with several coauthors from the same research group. Researchers must exercise caution not to draw cost-effectiveness conclusions by simply comparing the number of studies with favorable versus unfavorable economic findings without carefully assessing the representativeness and generalizability of evidence from country adaptation studies produced by the same research team. Collectively, findings from cost studies of localized RCC agreed that costs tended to rise with the aggressiveness of the local treatment. For RN, minimally invasive surgical techniques, such as laparoscopy with or without robotic assistance, were not necessarily associated with cost savings; however, for PN, robotic-assisted laparoscopic techniques appeared to have a cost advantage. This finding is consistent with what was reported in our previous review, in which laparoscopic PN was found to be cost saving compared with open PN [8] . The cost advantage of robotic-assisted procedures observed in PN might be partly due to the advanced technology filling the void of a greater need for improvement in the surgical skill required for PN (as compared with RN) [79] .
Three caveats for using the findings from our review to assist reimbursement decisions or guide clinical practice and future research are discussed below. First, the external validity to regions outside North America and Europe must be considered as only 10% of the studies (5 of 52) were from these regions. Second, although recent guidelines have different treatment recommendations for clear cell and non-clear cell mRCC [5] , our review did not differentiate these two subtypes of mRCC because this level of clinical detail was not provided in the studies we reviewed. Lastly, our quality assessment indicated that while the studies had largely met the reporting standards of the CHEERS checklist, one item that needs attention in future research is to better characterize heterogeneity, as it was addressed by approximately 20% of the studies in this review. The importance of subgroup analyses to understand heterogeneity is becoming increasingly important in economic studies in the era of personalized medicine.
Conclusion
In summary, RCC continued to exert considerable economic burden to the healthcare system. Although the treatment alternatives for RCC, especially mRCC, have substantially expanded in the past two decades, the cost effectiveness and budgetary impact of many new agents remain unexplored and represent areas in urgent need for future research to help patients, clinicians, and payers better navigate the changing landscape of treatment for RCC.
